Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (DE:137)
FRANKFURT:137
RESEARCH TOOLSreports
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -262.78K | $ -258.71K | $ -264.18K | $ -56.22K |
| Operating Income | $ -60.12T | $ -42.79M | $ -62.68M | $ -56.22M | $ -36.42M |
| EBITDA | $ -60.12T | $ -35.21M | $ -60.07M | $ -55.77M | $ -36.07M |
| Net Income | $ -55.85T | $ -37.54M | $ -61.37M | $ -59.25M | $ -37.55M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 10.00T> | $ 142.82M | $ 174.30M | $ 229.79M | $ 77.86M |
| Total Assets | $ 10.00T> | $ 148.33M | $ 181.29M | $ 233.14M | $ 83.35M |
| Total Debt | $ 15.30M | $ 15.66M | $ 16.08M | $ 15.86M | $ 15.33M |
| Net Debt | $ -39.22M | $ -127.17M | $ -128.34M | $ -213.93M | $ -62.53M |
| Total Liabilities | $ 33.60T | $ 28.53M | $ 30.28M | $ 27.40M | $ 23.84M |
| Stockholders' Equity | $ 71.00T | $ 119.80M | $ 151.01M | $ 205.74M | $ 59.51M |
| Cash Flow | |||||
| Free Cash Flow | $ -43.21T | $ -30.33M | $ -56.65M | $ -42.56M | $ -37.49M |
| Operating Cash Flow | $ -43.21T | $ -30.33M | $ -56.64M | $ -42.56M | $ -37.49M |
| Investing Cash Flow | $ -44.92T | $ 30.00M | $ -29.95M | $ -7.81K | $ 29.02M |
| Financing Cash Flow | $ -171.42B | $ -1.27M | $ 1.22M | $ 194.50M | $ 41.90M |